AxxessBio partners with companies globally to introduce innovations in Asia in the areas of speciality treatments.
We actively look for therapeutic solutions particularly in the areas of Hematology, Oncology, Neonatology, Rare Diseases, Metabolic Diseases and Other Speciality Therapeutics. Read more.
OUR MISSION
At AxxessBio, we bring the right treatments at the right time
By partnering with us, we develop a market access program to ensure your innovative therapies are made accessible to patients
We bring your innovative therapies to patients on an expedited basis prior to registration
AxxessBio is pleased to announce that Health Sciences Authority (HSA) Singapore has granted the registration rights to supply TEPADINA® (thiotepa) 100mg and TEPADINA® (thiotepa) 15mg with the following indications: With or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in
October 2020, Gennisium Pharma grants exclusive distribution rights to AxxessBio in Asia for Gencebok®. Gencebok® (caffeine citrate) is indicated for the treatment of primary apnea of premature newborns. Caffeine citrate is the standard treatment for this conditon. Apnea in preterm infants is common in babies born at less
October 2020, an exclusive agreement has been signed between AxxessBio and Dipharma SA for Sapropterin and Miglustat in selected countries in Asia. Sapropterin and Miglustat are medicines for rare metabolic diseases. Sapropterin is indicated for Phenylketonuria and BH4 Deficiency. Miglustat is indicated for Type 1 Gaucher Disease and Niemann-Pick C Disease.
Interested in Partnering Up?
At AxxessBio, we are continuously looking for partnerships to bring new innovative therapies for patients all around Asia
About Us
We bring innovative therapies & diagnostics to patients with rare diseases or unmet medical needs.
Address:
AxxessBio Pte Ltd, 36 Purvis Street, #02-05, Singapore 188613
Phone:
+65 6334 2518
Email:
Social:
AxxessBio is pleased to announce that Health Sciences Authority (HSA) Singapore has granted the registration rights to supply TEPADINA® (thiotepa) 100mg and TEPADINA® (thiotepa) 15mg with the following indications: With
Google Maps
© 2022 AxxessBio Pte Ltd. All Rights Reserved. Our Privacy Policy.
